Infectious Disease Therapeutics Market (2026 - 2033)

Infectious Disease Therapeutics Market Summary

The global infectious disease therapeutics market size was valued at USD 239.2 billion in 2025 and is projected to grow from USD 241.2 billion in 2026 to USD 323.3 billion by 2033, at a CAGR of 4.3% from 2026 to 2033. North America dominated the market, accounting for 37.7% of revenue in 2025. The market is expanding due to rising global health threats, increasing outbreaks of drug-resistant infections, and heightened awareness of disease prevention.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The growing burden of chronic infections like tuberculosis, hepatitis, and HIV/AIDS is driving sustained demand for effective treatments. Technological advancements in rapid diagnostics, immunotherapies, and personalized medicine enhance treatment efficacy.

To learn more about this report, Download Free Sample Report

The rising incidence of infectious diseases worldwide has driven strong demand for effective anti-infective agents. Diseases caused by bacteria, viruses, and fungi continue to rise, fueled by global travel, urbanization, and climate change, which facilitate the spread of pathogens across regions. This global health challenge necessitates a proactive approach to developing anti-infective agents to combat new and re-emerging diseases. Notable examples include recent outbreaks of Ebola and Zika, reinforcing the need for quick-response treatments. The COVID-19 pandemic highlighted this urgency, underscoring the critical role of targeted antiviral therapies in swiftly containing and treating high-impact infections.

To learn more about this report, Download Free Sample Report

HIV remains a major global public health challenge, with ongoing efforts to reduce new infections and expand treatment access. According to UNAIDS, 39.9 million people were living with HIV in 2023, including 38.6 million adults and 1.4 million children. Women and girls accounted for 53% of cases. In 2023, approximately 1.3 million people acquired HIV, reflecting a 39% decline since 2010 and 60% since 1995. Since 2003, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) has provided HIV testing for 71.1 million people and lifesaving ART for 20.5 million individuals. It has also enabled 5.5 million babies to be born HIV-free and supports over 327,000 healthcare workers worldwide.

A study published by the CDC stated that as of 2022, 296 million people globally were suffering from chronic hepatitis B infection. Around 820,000 deaths occur due to hepatitis B annually, causing 25% of chronic hepatitis B cases to ultimately progress to liver cancer. Rapid detection of infectious diseases with PCR facilitates timely intervention and can enable the delivery of appropriate treatments. For instance, the detection of tuberculosis is slow through conventional techniques, which can be overcome with molecular diagnostic tests for faster results.

Moreover, pharmaceutical companies are accelerating R&D to advance innovative therapies, including new classes of antibiotics, antivirals, and antifungals designed to combat resistance that threatens the efficacy of existing drugs. Investments in genomic analysis, artificial intelligence, and drug-repurposing platforms enable faster identification of promising drug candidates, streamlining development and shortening time to market, ultimately helping save more lives.

Overview Of Some Key Funding In The Infectious Disease Therapeutics Market

Source: Annual Reports, Press Release

Furthermore, collaborations and partnerships among large pharmaceutical companies, biotech firms, academic institutions, and research organizations strengthen R&D efforts in the infectious-disease therapeutics market. These alliances foster innovation by combining resources and expertise, leading to faster breakthroughs in treatment options. Such partnerships have proven essential in responding swiftly to emerging infectious diseases.

Market Dynamics

The infectious disease therapeutics market is supported by the continued burden of bacterial, viral, fungal, and parasitic infections, along with the growing need for effective treatment options. Rising antimicrobial resistance, increasing healthcare investments, and continued research in novel anti-infective therapies are supporting product development across multiple disease areas. Drug developers are focusing on new antibiotics, antivirals, and biologics to address resistant pathogens and emerging infectious diseases while improving treatment outcomes. Advances in rapid diagnostics are also enabling timely treatment decisions, supporting appropriate therapy selection, and improving patient management. At the same time, public health agencies and pharmaceutical companies are strengthening surveillance programs and expanding access to essential therapies through vaccination programs, infection control measures, and improved healthcare infrastructure. These factors continue to support steady demand for infectious disease therapeutics across hospital and outpatient care while encouraging ongoing investment in research and development for new treatment options.

Market Concentration & Characteristics

The infectious disease therapeutics industry continues to evolve with advancements in antiviral drugs, antibiotics, monoclonal antibodies, and vaccine development. Pharmaceutical companies focus on improving drug formulations, enhancing bioavailability, and developing combination therapies to address antimicrobial resistance. The market is witnessing increasing research into host-directed therapies, novel antimicrobial peptides, and immune-modulating agents to enhance treatment outcomes.

Mergers and acquisitions significantly shape the competitive landscape as pharmaceutical companies seek to expand their portfolios in vaccines, antivirals, and antibacterial treatments. Strategic acquisitions focus on strengthening research pipelines, securing proprietary drug formulations, and expanding market reach. The rising demand for novel therapies to combat drug-resistant pathogens and emerging infectious diseases is driving consolidation among key market players.

To learn more about this report, Download Free Sample Report

Regulatory agencies such as the FDA, EMA, and national health authorities enforce stringent approval processes for infectious disease therapeutics. Drug development must comply with rigorous clinical trial requirements, post-marketing surveillance, and pharmacovigilance protocols. Market access is significantly influenced by pricing regulations, reimbursement policies, and global health organizations' procurement strategies. Fast-track approvals and priority review programs support the development of treatments for high-burden infectious diseases, but regulatory compliance remains critical for market entry and expansion.

The market faces competition from preventive measures such as vaccines, sanitation improvements, and public health initiatives aimed at reducing disease transmission. Alternative therapeutic approaches, including passive immunization and convalescent plasma therapy, offer treatment options for specific infections. However, the continued emergence of resistant pathogens and the need for effective treatment regimens sustain the demand for pharmaceutical interventions, particularly in bacterial, viral, fungal, and parasitic infections.

Pharmaceutical companies are expanding into high-growth regions such as the Asia Pacific, Latin America, and Africa, driven by the increasing burden of infectious diseases, rising healthcare expenditure, and government-led treatment initiatives. Market growth is supported by partnerships with global health organizations, vaccine procurement programs, and funding from international agencies, all aimed at improving access to essential medicines. However, expansion efforts face challenges related to intellectual property rights, local manufacturing requirements, and pricing controls in emerging markets.

Analyst Perspective

The infectious disease therapeutics market continues to play an important role in global healthcare due to the ongoing burden of bacterial, viral, fungal, and parasitic infections. The market is supported by continuous development of new antibiotics, antivirals, antifungals, and vaccines to address antimicrobial resistance and emerging infectious diseases. Companies with broad anti-infective portfolios, established manufacturing capabilities, and global distribution networks continue to maintain a strong market position. Gilead Sciences remains a leading participant in antiviral therapies, particularly for HIV and viral hepatitis, while Merck & Co., Pfizer, AbbVie, and Roche continue to strengthen their infectious disease portfolios through product development and regulatory approvals. At the same time, generic manufacturers such as Sandoz, Xellia Pharmaceuticals, and Mankind Pharma support market growth by improving the availability of cost effective anti-infective therapies across developed and emerging healthcare markets.

Infection Insights

By infection type, the viral infections segment led the market with the largest revenue share of 40.7% in 2025. The rising prevalence of viral infections, including influenza, HIV, hepatitis, and emerging threats like COVID-19 and monkeypox, is a key driver in the market. Increasing globalization, urbanization, and climate change contribute to the rapid spread of viral diseases, fueling demand for antiviral drugs and vaccines. Advancements in biotechnology, RNA-based therapies, and monoclonal antibodies are accelerating treatment options. Governments and health organizations are investing in pandemic preparedness and vaccine development, further driving market growth.

The parasitic infections segment is the fastest-growing market, driven by increasing prevalence, rising drug resistance, and global health initiatives targeting malaria, leishmaniasis, and schistosomiasis. Pharmaceutical advancements focus on novel antiparasitic drugs, combination therapies, and repurposed treatments to address emerging resistance. Government programs, WHO-led eradication efforts, and funding from global health organizations further support market expansion. Growth is prominent in high-burden regions across Africa, Asia-Pacific, and Latin America, where improved access to therapeutics is a key priority.

Drug Class Insights

By drug class, the vaccines segment led the market with the largest revenue share of 31.4% in 2025, driven by rising disease prevalence, growing awareness, and robust government immunization programs. Emerging and re-emerging infections, such as COVID-19, influenza, HPV, and RSV, fuel demand for new and improved vaccines. Advances in mRNA, recombinant, and vector-based vaccine technologies enhance efficacy and speed up development. Increased R&D investments, global health initiatives, and regulatory support accelerate market growth. In addition, the expansion of pediatric and adult immunization programs, alongside rising concerns about antimicrobial resistance, boosts vaccine adoption.

The antiparasitic drugs segment is experiencing significant growth due to the rising prevalence of malaria, leishmaniasis, and other parasitic infections. Increasing drug resistance drives demand for novel formulations and combination therapies. Pharmaceutical companies are expanding research into next-generation antiparasitics, supported by global health initiatives and funding from organizations like the WHO. Growth is strongest in high-burden regions, including Africa, Asia-Pacific, and Latin America, where improved access to treatment and government-led eradication programs contribute to market expansion.

Distribution Channel Insights

Based on distribution channel, the hospital pharmacy segment led the market with the largest revenue share of 52.1% in 2025, driven by the rising number of hospitalizations globally. Hospitals offer comprehensive patient care, prompt reimbursement, and favorable insurance policies, making them a preferred choice for patients. Hospital pharmacies are typically found in large medical institutions with advanced healthcare facilities, often including specialized departments such as infectious disease or intensive care units, where patients with severe infections receive treatment.

To learn more about this report, Download Free Sample Report

The other distribution channel segment is experiencing rapid growth due to the increasing adoption of online pharmacies, which enhance accessibility and convenience for infectious disease therapeutics. E-commerce platforms enable direct-to-consumer sales, reducing dependency on traditional retail channels. Regulatory support for online drug sales and rising internet penetration are driving market expansion. Consumers prefer online platforms for affordability, availability, and doorstep delivery, especially in remote areas. The demand for antiparasitic drugs, antibiotics, and antivirals through online channels is rising, particularly in high-burden regions across the Asia-Pacific, Latin America, and Africa.

Regional Insights

North America dominated the infectious disease therapeutics market with the largest revenue share of 37.7% in 2025. Growth is driven by the high prevalence of bacterial, viral, and parasitic infections and increased adoption of antibiotics, antivirals, and antiparasitic drugs. The expanding use of vaccines and monoclonal antibodies is improving treatment outcomes. Hospital-based treatments dominate distribution, while retail and online pharmacies are witnessing growing demand for infectious disease management.

To learn more about this report, Download Free Sample Report

U.S. Infectious Disease Therapeutics Market Trends

The infectious disease therapeutics market in the U.S. held the largest share in the North America region in 2025. The infectious disease therapeutics market in the U.S. leads the North American market, supported by substantial biopharma investments, high R&D expenditure, and early regulatory approvals. Rising utilization of antiviral drugs, antibiotics, and combination therapies drives market growth. The expansion of hospital-based care, along with increased accessibility of outpatient treatments, supports market penetration. Government initiatives and strategic pharmaceutical collaborations further strengthen the market landscape.

Europe Infectious Disease Therapeutics Market Trends

The infectious disease therapeutics market in Europe is experiencing steady growth, led by Germany, France, and the UK. The region benefits from strong clinical research infrastructure, government support for infectious disease management, and increasing adoption of vaccines, antibiotics, and novel therapeutics. Hospitals hold the largest share of distribution, complemented by retail pharmacies and specialized infectious disease clinics.

The UK infectious disease therapeutics market is driven by increased funding for infectious disease research and expanding access to antiviral and antibiotic treatments. With ongoing clinical trials and collaborations between healthcare providers and pharmaceutical companies, the demand for monoclonal antibodies and vaccines is rising. Infectious disease clinics are gaining traction, complementing hospital-based treatment pathways.

The infectious disease therapeutics market in Germany remains a key market in Europe’s infectious disease therapeutics sector, supported by advanced manufacturing capabilities and robust biotech investments. Growing demand for antiviral medications, broad-spectrum antibiotics, and combination therapies is observed. Hospital-based treatment remains dominant, with retail pharmacies enhancing outpatient access.

The France infectious disease therapeutics market is driven by the increasing adoption of antiviral drugs, antibiotic therapies, and vaccines. Regulatory advancements and public healthcare initiatives are expanding market penetration. Hospitals remain the primary distribution channel, with retail pharmacies gaining prominence in outpatient care.

Asia Pacific Infectious Disease Therapeutics Market Trends

The infectious disease therapeutics market in the Asia Pacific is expanding due to the rising prevalence of bacterial and viral infections and improving healthcare infrastructure. Countries such as China, India, and Japan are leading the market, supported by increasing government initiatives and local manufacturing of antibiotics and vaccines. Hospital-based treatments and retail pharmacies are improving market penetration.

The Japan infectious disease therapeutics market growth is supported by government funding for infectious disease research and a growing focus on outbreak preparedness. Hospitals remain the dominant distribution channel, with specialized infectious disease clinics improving access to treatments.

The infectious disease therapeutics market in China is expanding rapidly, supported by robust biopharma investments and increased healthcare accessibility. The demand for antibiotics, antivirals, and vaccines is growing, with hospital-based care and online pharmacy platforms facilitating patient access to treatment.

Latin America Infectious Disease Therapeutics Market Trends

The infectious disease therapeutics market in Latin America is growing, driven by rising healthcare expenditures and increasing awareness of infection prevention. Brazil stands out as a key market, supported by government health initiatives and investments in biopharmaceutical development. The demand for antibiotics, vaccines, and antiviral medications is fostering market expansion.

Brazil's infectious disease therapeutics market growth is fueled by a high burden of infectious diseases and expanding healthcare infrastructure. Investments in local manufacturing of antibiotics and vaccines, along with international collaborations, are enhancing access to treatment. Hospital-based care remains dominant, while retail and online pharmacies expand their services.

Middle East & Africa Infectious Disease Therapeutics Market Trends

The infectious disease therapeutics market in MEA is experiencing steady growth due to improving healthcare infrastructure and a rising burden of bacterial and viral infections. Countries such as Saudi Arabia are witnessing increased demand for antibiotics, antivirals, and vaccines, driven by government initiatives aimed at healthcare modernization.

Saudi Arabia infectious disease therapeutics market is expanding, supported by healthcare reforms and growing investments in infectious disease research. The rising incidence of bacterial and viral infections is increasing the demand for treatment solutions, with hospital-based services leading distribution and retail pharmacies improving patient access.

Key Infectious Disease Therapeutics Company Insights

Leading pharmaceutical companies in the market focus on drug development, strategic partnerships, and global expansion. Companies such as Pfizer, Gilead Sciences, Merck & Co., and Roche dominate the infectious disease therapeutics segment, introducing novel antibiotics, antivirals, and vaccines. Mergers, acquisitions, and rising R&D investments are intensifying competition and driving product innovation and treatment accessibility in the market.

Recent Developments

• In February 2025, AbbVie and Pfizer’s EMBLAVEO (aztreonam and avibactam) received U.S. FDA approval, in combination with metronidazole, for adults with complicated intra-abdominal infections for whom treatment options are limited or nonexistent.

• In February 2024, AstraZeneca completed the acquisition of the U.S.-based clinical-stage biopharmaceutical company Icosavax for approximately USD 1.1 billion. The acquisition strengthened AstraZeneca’s vaccine pipeline with a Phase III-ready candidate for respiratory infections.

Global Infectious Disease Therapeutics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global infectious disease therapeutics market report based on infection, drug class, distribution channel, and region:

To learn more about this report, Download Free Sample Report

• Infection Outlook (Revenue, USD Million, 2021 - 2033)

  • Bacterial Infections

  • Viral Infections

    • Human Immunodeficiency Virus (HIV/AIDS)

    • Hepatitis (Hepatitis B, Hepatitis C)

    • Influenza

    • Others

  • Fungal Infections

  • Parasitic Infections

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)

  • Antibacterials

  • Antivirals

  • Antifungals

  • Antiparasitic Drugs

  • Vaccines

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The infectious disease therapeutics market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each infectious disease therapeutics segment quantified using the revenue-capture definitions in the table below.

Estimation Model 

The study incorporated a combination of primary and secondary research methodologies to evaluate the global infectious disease therapeutics market. Secondary research involved the review of company annual reports, investor presentations, regulatory filings, clinical practice guidelines, World Health Organization publications, Centers for Disease Control and Prevention reports, clinical trial databases, scientific publications, industry journals, and publicly available information from pharmaceutical companies and healthcare agencies. Epidemiology data, disease surveillance reports, treatment guidelines, and drug approval databases were also analyzed to assess disease burden, treatment patterns, and product availability across major markets. Primary research included interviews and discussions with pharmaceutical manufacturers, infectious disease specialists, microbiologists, hospital pharmacists, researchers, healthcare providers, business development executives, and key opinion leaders to validate epidemiology trends, prescribing patterns, treatment adoption, competitive developments, pricing trends, and future market opportunities. The findings from both research approaches were combined to ensure accurate market estimates and comprehensive industry analysis.

Delivered Customizations

This report has been delivered with the following In-depth customizations